TL;DR
$5M products liability is the floor for most pharma and medical device sponsor MSAs; $10M appears for oncology, biologics, sterile injectable, and controlled-substance work. Going from $5M to $10M typically adds $15K to $40K in annual premium for a mid-market CDMO. The $10M trigger is usually sponsor MSA wording, not statistical loss expectancy.
Products tower sizing
The products and completed operations tower is the single most important coverage line for most life-sciences operators. The sizing decision - typically between $5M and $10M, occasionally up to $25M or beyond - drives a meaningful share of total program premium and determines whether the operator is compliant with sponsor MSAs at the high end of the market.
This page covers the practical tradeoff: what each tower size satisfies, what it costs incrementally, and the breakpoints where stepping up from $5M to $10M moves from optional to mandatory.
Last updated 2026-05-12
Side-by-side
Frequently asked
Branded innovator sponsor MSAs, hospital purchase contracts at 503B scale, and most Class III medical-device GPO contracts typically require $10M products at minimum. Some innovator MSAs for biologics, oncology, or injectable products require $25M+. Generic-pharma sponsor MSAs typically accept $5M.
For a Texas CDMO at $20M revenue manufacturing oral solid dose, the premium delta is typically $15,000-$35,000 annually. For sterile injectables at the same revenue, the delta runs $30,000-$80,000+ depending on product class. The marginal cost is meaningful but smaller than the cost of being out of compliance on a single high-value engagement.
A products policy with $5M aggregate means total claims paid in one policy period are capped at $5M. A single $3M-$4M claim materially erodes the aggregate, leaving the operator under-insured for the remainder of the policy period. Operators serving multiple sponsors with shared aggregate face compounding exposure; per-project or per-location aggregate endorsements help.
Often yes - for two reasons. First, sponsor MSAs change at renewal; if a sponsor moves from $5M to $10M, the operator needs the tower ready. Second, aggregate exhaustion risk scales with sponsor count; multi-sponsor operators benefit from headroom even when no single MSA requires it.
Sometimes - specialty life-sciences markets writing monoline $10M occur. More commonly the tower is built in layers: $1M primary CGL/products + $4M umbrella + $5M excess from a second carrier. The layered structure is typically more economical than monoline at $10M.
Free coverage review